This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
VISION Trial
Treatment Considerations in the First Line Setting of mCRPC
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Clinical Trials
From the Editor
Search Clinical Trials
Transformative Trials
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
RSNA 2022
SUO 2022
Urologists for Social Responsibility 2023
Upcoming
ASCO GU 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2019
ESMO 2019
Prostate Cancer
Kidney Cancer
Bladder Cancer
Testicular Cancer
ESMO 2019 Kidney Cancer
Viewing 1-20 of 37 articles
ESMO 2019: Results from a Global Patient Survey: Diagnosis, Management, and Burden of Renal Cell Carcinomas - A Medical Oncologist’s Perspective
ESMO 2019: Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma
ESMO 2019: Invited Discussant: (911PD and 912PD) New Anti-Angiogenic Treatments for Kidney Cancer
ESMO 2019: Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: A Subgroup Analysis on Efficacy and Biomarkers from the Phase 3 JAVELIN Renal 101 Trial of First-Line Avelumab plus Axitinib versus Sunitinib
ESMO 2019: A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC - A Medical Oncologist's Perspective
ESMO 2019: ADAPTeR: Anti-PD1 Therapy as Operative Therapy in Metastatic Renal Cell Carcinoma
ESMO 2019: Phase 3 JAVELIN Renal 101 Trial of First-Line Avelumab + Axitinib vs. Sunitinib For Advanced Renal Cell Carcinoma
ESMO 2019: The Associated of CD8 Infiltration and PD-L1 Expression and Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab, NIVOREN GETUG-AFU 26 Translational Study
ESMO 2019: Phase 3 Trial of Adjuvant Sunitinib in Patients with High-risk Renal Cell Carcinoma: Comprehensive Tumor Genomic and Transcriptomic Analyses
ESMO 2019: Primary Renal Tumour Shrinkage in Patients who did not Undergo Upfront Cytoreductive Nephrectomy: Subgroup Analysis from Phase 3 JAVELIN Renal 101 Trial
ESMO 2019: Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus Axitinib Alone in Patients with Advanced or mRCC
ESMO 2019: Efficacy and Biomarker Analysis of Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: Subgroup Analysis from the Phase 3 JAVELIN Renal 101 Trial of First-line Avelumab Plus Axitinib vs Sunitinib
ESMO 2019: A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC
ESMO 2019: Phase 3 Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Comprehensive Tumor Genomic and Transcriptomic Analyses
ESMO 2019: NIVOREN GETUG-AFU 26 Translational Study: CD8 Infiltration and PD-L1 Expression are Associated with Outcome in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab
ESMO 2019: Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries
ESMO 2019: ADAPTeR - Phase II study of Anti-PD1 Therapy as Pre- and Post-Operative Therapy in Metastatic Renal Cell Carcinoma
ESMO 2019: Efficacy and Biomarker Analysis of Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: Subgroup Analysis from the Phase III JAVELIN Renal 101 Trial
ESMO 2019: Results of the Phase II TRAXAR Study: A Randomized Phase II Trial of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma
ESMO 2019: Invited Discussant: Germ Cell Tumor Studies and Renal Cell Carcinoma Disease Management Methods
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free